- Hypersensitivity Reactions to Antineoplastic Agents: Characteristics and Premedication Strategies
-
Lee SY, Kim HJ, Jeong J, Kang HR
- KMID: 2551228
- Pharmacoepidemiol Risk Manage.
- 2023 Sep;15(2):117-127.
- doi: 10.56142/perm.23.0019
All antineoplastic agents can potentially cause hypersensitivity reactions. Hypersensitivity reactions to antineoplastic agents may not provide patients with optimal treatment and may affect future survival. Hypersensitivity reactions to antineoplastic agents are... -
- CITED
-
- Close
- SHARE
-
- Close
- Prenatal Topiramate Exposure and Risk of Neurodevelopmental Disorders: A Systematic Review
-
Lim DJ, Jeong J, Lee JM, Lee M, Lee JY
- KMID: 2551226
- Pharmacoepidemiol Risk Manage.
- 2023 Sep;15(2):101-106.
- doi: 10.56142/perm.23.0005
Objective: This systematic review aimed to investigate the potential risk of neurodevelopmental disorders resulting from fetal exposure to topiramate. Methods: A comprehensive search was conducted in major foreign databases, including PubMed... -
- CITED
-
- Close
- SHARE
-
- Close
- Lessons from US FDA's COVID-19 Related Post-Marketing Drug Safety Monitoring and Evaluation Activities
-
Lee HJ, Lee JW, Park SY, Seong SH, Jung SY
- KMID: 2551227
- Pharmacoepidemiol Risk Manage.
- 2023 Sep;15(2):107-116.
- doi: 10.56142/perm.23.0013
World Health Organization (WHO) has declared the termination of a public health emergency of international concern (PHEIC) about COVID-19 and regulatory authorities diminished the level of crisis response and transitioned... -
- CITED
-
- Close
- SHARE
-
- Close
- Nationwide Use of High-Alert Medications
-
Jeong J, Lee S, Lee AY, Heo KN, Park S, Chae H, Lee JY, Min Si, Ah YM, Han JM
- KMID: 2551232
- Pharmacoepidemiol Risk Manage.
- 2023 Sep;15(2):157-164.
- doi: 10.56142/perm.23.0015
Objective: This study aimed to estimate the rate of high-alert medication (HAM) use in nationwide representative claims data and compare the rates by types of healthcare settings. Methods: This cross-sectional... -
- CITED
-
- Close
- SHARE
-
- Close
- Enhancing Safety of Heparin Administration: An Analysis of Prolonged aPTT and Bleeding in Patients Receiving Heparin
-
Chung H, Baek JU, Kim KA, Kang H, Cho EJ, Cho YS, Lee JY, Kim AJ
- KMID: 2551234
- Pharmacoepidemiol Risk Manage.
- 2023 Sep;15(2):172-180.
- doi: 10.56142/perm.23.0017
Objective: Heparin, a high-risk medication with narrow therapeutic range, poses a significant risk to patient safety due to fatal accidents resulting from administration errors. This study aimed to analyze the... -
- CITED
-
- Close
- SHARE
-
- Close
- Adverse Events Related to Zolpidem in the Korea Pharmaceutical Association Adverse Event Reporting System
-
Hwang SH, Ha MY, Lee CY, Lee MS, Kim YW, Lee JM, Shin JY
- KMID: 2551230
- Pharmacoepidemiol Risk Manage.
- 2023 Sep;15(2):137-144.
- doi: 10.56142/perm.23.0012
Objective: Zolpidem is a non-benzodiazepine drug that is known for its relative safety benefit compared to traditional benzodiazepines. However, adverse events (AEs) on the central nervous system such as somnambulism,... -
- CITED
-
- Close
- SHARE
-
- Close
- A Cross Sectional Study of High-Alert Medications and Their Potential Harm in Acute Care Settings
-
Lee AY, Han JM, Jeong J, Lee S, Heo KN, Park S, Chae H, Min Si, Ah YM, Lee JY
- KMID: 2551233
- Pharmacoepidemiol Risk Manage.
- 2023 Sep;15(2):165-171.
- doi: 10.56142/perm.23.0016
Objective: In this study, we aimed to analyze national claims data to assess the usage of high-alert medications among hospitalized patients and to identify associated potential harm. Methods: This study... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of Clinical Outcomes of Dual Antiplatelet Therapy in Elderly Patients with Percutaneous Coronary Intervention
-
Choi JH, Lee S
- KMID: 2551231
- Pharmacoepidemiol Risk Manage.
- 2023 Sep;15(2):145-156.
- doi: 10.56142/perm.23.0014
Objective: Dual antiplatelet therapy (DAPT) has been used following percutaneous coronary intervention (PCI) to prevent major adverse cardiovascular events (MACEs). This study aimed to analyze cardiovascular events and bleeding incidents in... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of Treatment-Related Adverse Events in Hospitalized Patients with Coronavirus Disease 2019
-
Lee SB, Lee DY, Kim JH, Moon SH, Lee G, Choi B, Kim YS, Im JH, Kang DY
- KMID: 2551229
- Pharmacoepidemiol Risk Manage.
- 2023 Sep;15(2):128-136.
- doi: 10.56142/perm.23.0010
Objective: This study aimed to assess the status and characteristics of adverse events caused by treatments of coronavirus disease 2019 (COVID-19) in hospitalized patients in Korea. Methods: The medical records of... -
- CITED
-
- Close
- SHARE
-
- Close
